Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The Alzheimer's Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer's disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation.
Característiques principals

2012 RESEARCH FUNDING PRIORITIES
The ADDF funds four different categories of research: drug discovery and preclinical development, early detection, clinical trials and prevention. The ADDF does not fund basic research.

The ADDF is interested in novel targets and therapeutic approaches for Alzheimer’s disease, related dementias and cognitive aging. These areas include, but are not limited to: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers. The ADDF has limited interest in funding anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs.

FUNDING MECHANISMS:
  • Cohorts for Alzheimer’s Prevention Action (CAPA) Consortium RFP: specific analyses across a minimum of 5 longitudinal cohorts to examine the association of actionable interventions with the risk of cognitive aging, Alzheimer’s disease, related dementias, or biomarkers related to brain aging and neurodegeneration. The full application (with a letter-of-support from each cohort participating in the proposal) is due on March 5, 2015
  • Preclinical Drug Discovery RFP: promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive ageing.
  • Program to Accelerate Clinical Trials (PACT) RFP: biomarker-based, proof-of-concept pilot clinical trials for Alzheimer’s
  • ADDF/NIH RFP: assistance for relevant NIH grant applications that were scored but not funded in response to certain NIH funding opportunities. Application deadline is rolling
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    http://www.alzdiscovery.org/research-and-grants/funding-opportunities
    Dotació
    100,000-$300,000 per year depending on the stage of the project
    Durada
    1 year.
    In some cases, multi-year proposals can be considered.
    AVÍS IMPORTANT
    Deadlines for 2015 RFPs: March 10, June 16, September 22, December 10 **Letter of intent is due at least two weeks prior to each deadline for consideration in that funding cycle (except for the CAPA Consortium )

    Arxius

    Arxiu
    NIH-ADDF
    PACT
    Preclinical Drug Discovery
    CAPA